ArticleThe oncologist2025

Sacituzumab govitecan in the first-line treatment of triple-negative breast cancer: balancing therapeutic sequencing with patient-relevant benefits.

Dario Trapani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.